First Time Loading...

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 20.52 USD -1.2%
Updated: Mar 29, 2024

Intrinsic Value

DNLI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. [ Read More ]

The intrinsic value of one DNLI stock under the Base Case scenario is 24.53 USD. Compared to the current market price of 20.52 USD, Denali Therapeutics Inc is Undervalued by 16%.

Key Points:
DNLI Intrinsic Value
Base Case
24.53 USD
Undervaluation 16%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Denali Therapeutics Inc

Backtest DNLI Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DNLI stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Denali Therapeutics Inc

Current Assets 1.1B
Cash & Short-Term Investments 1B
Other Current Assets 29.6m
Non-Current Assets 89.8m
PP&E 71.6m
Other Non-Current Assets 18.1m
Current Liabilities 78m
Accounts Payable 9.5m
Accrued Liabilities 68.5m
Non-Current Liabilities 45m
Other Non-Current Liabilities 45m
Efficiency

Earnings Waterfall
Denali Therapeutics Inc

Revenue
330.5m USD
Operating Expenses
-527.2m USD
Operating Income
-196.7m USD
Other Expenses
51.5m USD
Net Income
-145.2m USD

Free Cash Flow Analysis
Denali Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DNLI Profitability Score
Profitability Due Diligence

Denali Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Negative 3-Years Revenue Growth
Negative Revenue Growth Forecast
Declining ROE
17/100
Profitability
Score

Denali Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

DNLI Solvency Score
Solvency Due Diligence

Denali Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Denali Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DNLI Price Targets Summary
Denali Therapeutics Inc

Wall Street analysts forecast DNLI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DNLI is 44.75 USD with a low forecast of 26.26 USD and a high forecast of 99.75 USD.

Lowest
Price Target
26.26 USD
28% Upside
Average
Price Target
44.75 USD
118% Upside
Highest
Price Target
99.75 USD
386% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DNLI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DNLI Price
Denali Therapeutics Inc

1M 1M
+4%
6M 6M
-1%
1Y 1Y
-11%
3Y 3Y
-62%
5Y 5Y
-12%
10Y 10Y
-4%
Annual Price Range
20.52
52w Low
15.83
52w High
32.96
Price Metrics
Average Annual Return 57.02%
Standard Deviation of Annual Returns 183.61%
Max Drawdown -83%
Shares Statistics
Market Capitalization 2.8B USD
Shares Outstanding 139 160 000
Percentage of Shares Shorted 7.55%

DNLI Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Denali Therapeutics Inc Logo
Denali Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.8B USD

Dividend Yield

0%

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 380 full-time employees. The company went IPO on 2017-12-08. The firm is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The firm clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The firm engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.

Contact

CALIFORNIA
South San Francisco
161 Oyster Point Blvd
+16508668548.0
https://www.denalitherapeutics.com

IPO

2017-12-08

Employees

380

Officers

Co-Founder, President, CEO & Director
Dr. Ryan J. Watts Ph.D.
Co-Founder, CFO, COO & Secretary
Dr. Alexander O. Schuth M.D.
Co-Founder & Independent Director
Dr. Marc Tessier-Lavigne Ph.D.
Chief Medical Officer & Head of Development
Dr. Carole Ho M.D.
Senior Vice President of Corporate Finance
Mr. Tyler M. Nielsen
Chief Technical and Manufacturing Officer
Dr. Dana Andersen
Show More
Chief Scientific Officer
Mr. Joe Lewcock Ph.D.
Vice President of Investor Relations
Dr. Laura Hansen
General Counsel
Mr. Chris Walsh
Vice President of Corporate Development
Mr. Mark Rowen
Show Less

See Also

Discover More
What is the Intrinsic Value of one DNLI stock?

The intrinsic value of one DNLI stock under the Base Case scenario is 24.53 USD.

Is DNLI stock undervalued or overvalued?

Compared to the current market price of 20.52 USD, Denali Therapeutics Inc is Undervalued by 16%.